Most patients experience minimal to no pain during semaglutide injection because the needle is extremely thin (2931 gauge)
Research applications for semaglutide have encompassed receptor binding kinetics and selectivity characterization at GLP-1R, downstream intracellular cAMP signaling cascade analysis, pancreatic cell line pharmacological studies, and comparative structural investigations relative to first-generation GLP-1 receptor agonist peptides
Hiromichi Wakui has received research supports from AstraZeneca, Otsuka Pharmaceutical, and Kaneka Corporation, and honoraria from AstraZeneca, Otsuka Pharmaceutical, Kaneka Corporation, Kyowa Kirin, Sanwa Kagaku, Chugai Pharma, Kowa, Otsuka Pharmaceutical, Novartes, Mitsubishi-Tanabe Pharma, Bayer, and Daiichi-Sankyo Pharma
Join us for this free, non-CE webinar to stay informed and provide enhanced care
doi:10.1016/j.ejmg.2014.10.004 [5] Fdinger M, Hrl WH, Sunder-Plassmann G
So, he has options